AMBRISENTAN (ambrisentan) by Gilead Sciences is endothelin receptor antagonists [moa]. Approved for pulmonary arterial hypertension (pah) (who group 1) in adult patients: to improve exercise ability, delay clinical worsening, hypertension. First approved in 2022.
Drug data last refreshed 19h ago
Endothelin Receptor Antagonists
Endothelin Receptor Antagonist
Worked on AMBRISENTAN at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension
Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study